We found that the main types of biologics currently applied to AA amyloidosis include anti-TNFα agents [IFX (57, 61, 67, 72, 73, 84), adalimumab (56, 98, 99), and etanercept (54, 66, 68, 79)], anti-IL-1 agents [anakinra (49, 51, 52, 58, 64, 69, 71, 75, 80, 81) and canakinumab (59, 77)], and anti-IL-6 agents [[tocilizumab (53, 55, 60, 62, 63, 74, 76, 78, 82, 83)]. Here, IL6 is linked to AA amyloidosis.